Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05309720
Other study ID # 2022-13625
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 1, 2022
Est. completion date November 1, 2025

Study information

Verified date November 2023
Source Radboud University Medical Center
Contact Milly van de Warenburg, MD
Phone 0031 24 361 1111
Email milly.vandewarenburg@radboudumc.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The standard treatment of deep dermal to full thickness burns is surgical removal of the burn followed by skin transplantation. Dermal substitutes are increasingly used in the treatment of deep burns to replace lost dermis. Preservation of the collagen and elastin in the acellular human dermal substitute Glyaderm provides a more elastic scar. It is unknown what the effect of Glyaderm on scar quality is in a solely paediatric population. The objective of this case series is to investigate scar maturation and scar quality when applying Glyaderm in deep dermal to full thickness burns in a pediatric population aged ≤15 years old.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date November 1, 2025
Est. primary completion date November 1, 2025
Accepts healthy volunteers No
Gender All
Age group N/A to 15 Years
Eligibility Inclusion Criteria: 1. Age =15 years old 2. Burn wounds requiring skin grafting 3. Written informed consent provided by 1. The participant's parent(s)/guardian (<12 years of age) 2. The participant's parent(s)/guardian and the participant itself (12-15 years old) Exclusion Criteria: 1. Burn wound of =30 cm2 2. Infected burn wounds: clinical symptoms in combination with positive wound swabs 3. Patients/parents with insufficient knowledge of the Dutch or English language, since they would not be able to complete the POSAS questionnaire.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Glyaderm
All included patients will undergo full thickness removal of the burned skin or adequate debridement of all necrotic tissue. Next, the dermal substitute Glyaderm followed by a split thickness skin graft will be transplanted on the wound.

Locations

Country Name City State
Netherlands Radboudumc Nijmegen

Sponsors (1)

Lead Sponsor Collaborator
Radboud University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Scar quality (clinician) Scar quality measured using the Patient and Observer Scar Assessment Scale (POSAS) Observer Scale, which rates the scar from 1 (=like normal skin) to 10 (=worst scar imaginable). 12 months
Secondary Clinical assessment of the graft take Take of the split thickness skin graft (STSG) in percentages. The take is defined as STSG that appears vital and is adherent to the wound bed. 5-7 days after STSG application
Secondary Wound epithelialization Wound epithelialization is the percentage of the graft with a vital skin graft and healed graft interstices. 5-7 days after STSG application
Secondary Wound healing time >95% epithelialization of the wound area is considered as healed determined in the first several days to weeks after STSG application
Secondary Donor site healing time >95% epithelialisation of the donor site wound surface area is considered as healed determined in the first several days to weeks after STSG application
Secondary Scar surface area The scar surface area is calculated using the surgery wound as reference area day of surgery (day 0) and 3, 6 and 12 months post-surgery
Secondary Scar quality (participant) Scar quality measured using the Patient and Observer Scar Assessment Scale (POSAS) Patient Scale, rating the scar from 1 (=like normal skin) to 10 (=worst scar imaginable). 3, 6 and 12 months post-surgery
Secondary Occurrence of scar contractures Scar contractures often occur in children with deep dermal and full thickness burn wounds. Up to 12 months post-surgery
Secondary Occurrence of scar hypertrophy Scar hypertrophy often occurs in children with deep dermal and full thickness burn wounds. Up to 12 months post-surgery
Secondary Range of motion of affected joints When joints are affected due to the burn wound, the range of motion of the affected joint(s) will be monitored during follow-up. 3, 6 and 12 months post-surgery
See also
  Status Clinical Trial Phase
Completed NCT05023135 - DeepView SnapShot Portable (DV-SSP): Device Training Study
Completed NCT05276869 - Reliability and Feasibility of WeeFIM Instrument to Measure Functional Independence in Pediatric Burns
Completed NCT04548635 - VR for Burn Dressing Changes at Home Phase 2/Phase 3
Not yet recruiting NCT06076031 - Effects of Applying Streaming Media on Reducing Pain in Patient With Second-degree Burn During Changing Dressing N/A
Recruiting NCT05084248 - Vitamin D Deficiency in Adults Following a Major Burn Injury Phase 4
Completed NCT03113253 - TRANexamic Acid to Reduce Bleeding in BURN Surgery Phase 4
Recruiting NCT04090424 - Assessment of Safety and Effectiveness of NovoSorb® BTM in Severe Burns N/A
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Withdrawn NCT03159182 - Study of Silicone Material Inserts To Treat Burn Scars N/A
Recruiting NCT02904941 - Human Amniotic Versus Synthetic Membrane as a Transient Skin Cover for Pediatric Burns N/A
Completed NCT02681757 - Comparison of Mepitel Ag vs Antibiotic Ointment Used With Soft Cast Technique for Treatment of Pediatric Burns N/A
Recruiting NCT01812941 - Evaluation of Mitochondrial Dysfunction in Severe Burn and Trauma Patients N/A
Completed NCT01437852 - StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns Phase 1
Completed NCT01214811 - Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing Phase 3
Completed NCT01061502 - Efficacy Study of a Bioelectric Dressing to Treat Skin Graft Donor Site Wounds Phase 1/Phase 2
Terminated NCT00822796 - Thermogard™ Efficacy Trial N/A
Terminated NCT00824681 - Effect of Music Therapy on Families of Burn Patients Phase 1
Terminated NCT00634166 - Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group Phase 4
Terminated NCT00464386 - Continuous Glucose Monitoring (POC) in the ICU N/A
Withdrawn NCT00216983 - Proline Metabolism in Severely Burned Patients: Effect of Modulated Parenteral Feeding N/A